Rahnama'i and colleagues highlight the emerging role of selective phosphodiesterase (PDE) inhibitors in the management of functional voiding disorders. Although much remains unknown about the role of these enzymes in the human bladder, accumulating evidence suggests that PDE5 inhibitors alleviate lower urinary tract symptoms in men, and could be a useful adjunct to α blocker therapy.
- Mohammad S. Rahnama'i
- Stefan Ückert
- Gommert A. van Koeveringe
